INTRODUCTION: Achieving viral suppression is key in the global strategy to end the HIV epidemic. However, the levels of viral suppression have yet to be described in many resource-limited settings. METHODS: We investigated the time to virologic failure (VF; defined as a viral load of ≥1000 copies/ml) and changes in CD4 counts since starting antiretroviral therapy (ART) in a cohort of HIV-infected adults in Hanoi, Vietnam. Factors related to the time to VF and impaired early immune recovery (defined as not attaining an increase in 100 cells/mm3 in CD4 counts at 24 months) were further analysed. RESULTS: From 1806 participants, 225 were identified as having VF at a median of 50 months of first-line ART. The viral suppression rate at 12 months was 95.5% and survival without VF was maintained above 90% until 42 months. An increase in CD4 counts from the baseline was greater in groups with lower baseline CD4 counts. A younger age (multivariate hazard ratio (HR) 0.75, vs. <30), hepatitis C (HCV)-antibody positivity (HR 1.43), and stavudine (d4T)-containing regimens (HR 1.4, vs. zidovudine (AZT)) were associated with earlier VF. Factors associated with impaired early immune recovery included the male sex (odds ratio (OR) 1.78), HCV-antibody positivity (OR 1.72), d4T-based regimens (OR 0.51, vs. AZT), and nevirapine-based regimens (OR 0.53, vs. efavirenz) after controlling for baseline CD4 counts. CONCLUSION: Durable high-rate viral suppression was observed in the cohort of patients on first-line ART in Vietnam. Our results highlight the need to increase adherence support among injection drug users and HCV co-infected patients.
INTRODUCTION: Achieving viral suppression is key in the global strategy to end the HIV epidemic. However, the levels of viral suppression have yet to be described in many resource-limited settings. METHODS: We investigated the time to virologic failure (VF; defined as a viral load of ≥1000 copies/ml) and changes in CD4 counts since starting antiretroviral therapy (ART) in a cohort of HIV-infected adults in Hanoi, Vietnam. Factors related to the time to VF and impaired early immune recovery (defined as not attaining an increase in 100 cells/mm3 in CD4 counts at 24 months) were further analysed. RESULTS: From 1806 participants, 225 were identified as having VF at a median of 50 months of first-line ART. The viral suppression rate at 12 months was 95.5% and survival without VF was maintained above 90% until 42 months. An increase in CD4 counts from the baseline was greater in groups with lower baseline CD4 counts. A younger age (multivariate hazard ratio (HR) 0.75, vs. <30), hepatitis C (HCV)-antibody positivity (HR 1.43), and stavudine (d4T)-containing regimens (HR 1.4, vs. zidovudine (AZT)) were associated with earlier VF. Factors associated with impaired early immune recovery included the male sex (odds ratio (OR) 1.78), HCV-antibody positivity (OR 1.72), d4T-based regimens (OR 0.51, vs. AZT), and nevirapine-based regimens (OR 0.53, vs. efavirenz) after controlling for baseline CD4 counts. CONCLUSION: Durable high-rate viral suppression was observed in the cohort of patients on first-line ART in Vietnam. Our results highlight the need to increase adherence support among injection drug users and HCV co-infected patients.
Authors: James H McMahon; Julian H Elliott; Silvia Bertagnolio; Rachel Kubiak; Michael R Jordan Journal: Bull World Health Organ Date: 2013-02-21 Impact factor: 9.408
Authors: M R Jordan; Y Obeng-Aduasare; H Sheehan; S Y Hong; N Terrin; D V Duong; N V Trung; C Wanke; N V Kinh; A M Tang Journal: Int J STD AIDS Date: 2013-12-18 Impact factor: 1.359
Authors: Dam Anh Tran; David P Wilson; Anthony Shakeshaft; Anh Duc Ngo; Christopher Doran; Lei Zhang Journal: Sex Transm Infect Date: 2014-03-11 Impact factor: 3.519
Authors: Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A Mills; Guy de Bruyn; Ian Sanne; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Heather Ribaudo; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Thomas R Fleming Journal: N Engl J Med Date: 2011-07-18 Impact factor: 91.245
Authors: Gilbert R Kaufmann; Luc Perrin; Guiseppe Pantaleo; Milos Opravil; Hansjakob Furrer; Amalio Telenti; Bernard Hirschel; Bruno Ledergerber; Pietro Vernazza; Enos Bernasconi; Martin Rickenbach; Matthias Egger; Manuel Battegay Journal: Arch Intern Med Date: 2003-10-13
Authors: Mary van den Berg-Wolf; Katherine Huppler Hullsiek; Grace Peng; Michael J Kozal; Richard M Novak; Li Chen; Lawrence R Crane; Rodger D Macarthur Journal: HIV Clin Trials Date: 2008 Sep-Oct
Authors: Carina Cesar; Cathy A Jenkins; Bryan E Shepherd; Denis Padgett; Fernando Mejía; Sayonara Rocha Ribeiro; Claudia P Cortes; Jean W Pape; Juan Sierra Madero; Valeria Fink; Omar Sued; Catherine McGowan; Pedro Cahn Journal: Lancet HIV Date: 2015-10-22 Impact factor: 12.767
Authors: Thuc Minh Thi Vu; Victoria L Boggiano; Bach Xuan Tran; Long Hoang Nguyen; Tung Thanh Tran; Carl A Latkin; Cyrus S H Ho; Roger C M Ho Journal: Int J Environ Res Public Health Date: 2018-05-29 Impact factor: 3.390
Authors: Todd M Pollack; Hao T Duong; Thuy T Pham; Thang D Nguyen; Howard Libman; Long Ngo; James H McMahon; Julian H Elliott; Cuong D Do; Donn J Colby Journal: J Int AIDS Soc Date: 2019-03 Impact factor: 5.396
Authors: Shoko Matsumoto; Hoai Dung Thi Nguyen; Dung Thi Nguyen; Giang Van Tran; Junko Tanuma; Daisuke Mizushima; Kinh Van Nguyen; Shinichi Oka Journal: BMC Int Health Hum Rights Date: 2020-01-10